Dernières nouvelles pour Genius Sports (NYSE:GENI) Stock

Genius Sports

Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.

Genius Sports Ltd

GENIUS PRODS INC by Genius Products, Inc.

Genie Energy Ltd. Class B Common Stock Stock

Genie Energy Ltd

Genius Group Ltd

Genius Metals Inc

GENIX PHARMACEUTICALS CP by GENIX PHARMACEUTICALS CORP.

Genix Pharmaceuticals Corp

Loop Capital analyst Mark Schappel maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Buy and lowers the price target from $310 to $300.

News

Price Target

Analyst Ratings

MNDY

Loop Capital Maintains Buy on Monday.Com, Lowers Price Target to $300

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

Reiteration

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

<a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf" title="https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf">https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf</a>

Global

Dr. Reddy's Laboratories Forms New Subsidiary In Finland, 'Dr. Reddy's Finland Oy', As Step-Down Wholly-Owned Entity

6th National Domestic Violence Project in Europe Strengthens SuperCom's Position as a Leader in the Space
TEL AVIV, Israel, Dec. 23, 2024 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today the successful launch of its new electronic monitoring (EM) project in Latvia. Following a competitive tender process, SuperCom was awarded this project, marking its third national contract in Latvia and further expanding its role in supporting the country's public safety efforts with the inclusion of domestic violence prevention.
Under this program, SuperCom is deploying its advanced PureSecurity EM Suite, featuring GPS tracking devices, secure communications, and real-time monitoring capabilities. SuperCom's technology will enhance the State Police of Latvia's ability to oversee offenders, enabling more effective prevention and response to domestic violence cases while bolstering regional public safety and security.

Contracts

SPCB

SuperCom Awarded New Domestic Violence Monitoring Project Using It's PureSecurity EM Suite, With The State Police Of Latvia

Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and raises the price target from $15 to $17.

HUMA

Benchmark Maintains Buy on Humacyte, Raises Price Target to $17

Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) shares are surging premarket on Monday after the company disclosed a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643653/despegar-com-enters-into-merger-agreement-to-be-acquired-by-prosus-for-19-50-per-share-in-cash" rel="noreferrer noopener">deal to be acquired</a> by Prosus for $19.50 per share in an all-cash transaction.
The transaction price reflects a 34% premium over Despegar&#8217;s 90-day volume-weighted average share price as of December 20, 2024.
Despegar&#8217;s Board of Directors has approved the merger agreement and recommended shareholder approval following the unanimous endorsement of a Transaction Committee composed of independent directors.
The deal values Despegar at approximately $1.7 billion in enterprise value.
Despegar will gain access to Prosus&#8217; extensive resources, operational expertise, and advanced AI capabilities.
As per the deal, a wholly owned subsidiary of Prosus will merge with Despegar, with Despegar remaining as the surviving entity.
Each outstanding share of Despegar will be converted into the right to receive $19.50 in cash, while the company&#8217;s Series A Preferred Shares will be canceled and converted into payments as specified by their terms.
The transaction is anticipated to close in the second quarter of 2025, pending shareholder approval, regulatory clearances, and other <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643979/prosus-to-acquire-latin-americas-leading-online-travel-agency-despegar-for-us-1-7bn" rel="noreferrer noopener">customary closing conditions</a>.
Following the transaction&#8217;s completion, Despegar will transition to a privately held company. Its ordinary shares will be delisted from the New York Stock Exchange and will no longer trade on any public market.
Damian Scokin, Despegar&#8217;s CEO said, &#8221;Our customers will benefit from access to more services, enhanced customer experiences, increased loyalty benefits, and more comprehensive solutions tailored to their needs. Together we are setting the stage for a new era of travel marked by greater connectivity, innovation and value.&#8221;
Fabricio Bloisi, CEO of Prosus Group, added, &#8220;Despegar adds significantly to our strong ecosystem in Latin America, a market with amazing growth potential. Today&#8217;s announcement is about opportunity and growth &#8211; alone Despegar is a successful business with great fundamentals and a motivated management team; together, both Despegar and Prosus will make it even stronger.&#8221;
Investors can gain exposure to the DESP via Amplify ETF Trust Amplify Travel Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWAY#NYSE">AWAY</a>) and Global X MSCI Argentina ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARGT#NYSE">ARGT</a>).
Price Action: DESP shares are up 32.80% at $19.45 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42643303" target="_blank" rel="noreferrer noopener">US Stocks To Open Higher As Wall Street Expects &#8216;Santa Rally&#8217; In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus</a></li>
</ul>
Photo by Capri23auto from Pixabay

Equities

Mid Cap

Movers

ARGT

AWAY

DESP

Despegar To Be Acquired By Prosus For $1.7 Billion in All Cash Deal

<ul>
<li>TLRY</li>
<li>TSLA</li>
<li>AMD</li>
<li>NVDA</li>
<li>LUNR</li>
<li>PLTR</li>
<li>CORN</li>
<li>MSTR</li>
<li>KULR</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

CORN

KULR

LUNR

MSTR

NVDA

PLTR

TLRY

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 23, 2024 (Via Swaggy Stocks)

On December 23, 2024, ReNew Energy Global Plc ("ReNew") announced the signing of definitive agreement to sell ReNew Sun Waves Private Limited ("RSWPL"), which houses a 300 MW operating solar asset to Anzen India Energy Yield Plus Trust ("Anzen"). The transaction is expected to close post completion of contractual obligations and conditions precedent including receipt of lender approval. Under the agreement, ReNew Private Limited, parent of RSWPL, will sell 100% shareholding and economic interest in RSWPL. The enterprise value determined under the agreement is ~$176 million&#x2A;, subject to net current assets and other such adjustments as provided in the definitive documents. Additionally, ~$17 million&#x2A; is expected to be received as an earn-out on account of change in law proceeds pertaining to increase in basic customs duty (BCD), safeguard duty (SGD) and goods &amp; service tax (GST), after the first payment is realised by RSWPL. The 300 MW SECI solar project is located in Jaisalmer, Rajasthan, and has been operational for ~3 years. The tariff for the 25-year power purchase agreement is INR 2.55/unit.

Asset Sales

ReNew Energy Global Announced Sale Of ReNew Sun Waves' 300 MW Solar Asset To Anzen India Energy Yield Plus For ~$176M; ~$17M Earn-Out Expected; The Tariff For The 25-Year Power Purchase Agreement Is INR 2.55/Unit

Benchmark analyst Michael Albanese reiterates Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) with a Buy and maintains $70 price target.

Benchmark Reiterates Buy on Winnebago Industries, Maintains $70 Price Target

Offerings

MGOL

MGO Global Prices Upsized $6M Public Offering Of 6.32M Units At $0.95 Per Unit; Includes Common Stock And Warrants Exercisable At $1.425 Pending Stockholder Approval; Closing Expected December 24, 2024

--Multi-year Agreement with ADT for Several Servicing Needs--
Spruce Power Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) ("Spruce" or the "Company") today announced the first customer for its Spruce Pro servicing business. Spruce signed a multi-year Service Agreement with ADT, under which Spruce Pro will facilitate the management and resolution of workmanship and equipment warranty claims for customers of ADT's former solar business, which it wound down earlier in 2024.

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Announces Multi-Year Agreement With ADT For Several Servicing Needs Of ADT's Former Solar Business

Battle lines are drawn in <a href="https://www.benzinga.com/topic/defense">the defense sector</a>. On one side, Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) riding high on a meteoric stock surge of over 350% this year. On the other, defense titan Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), grappling with sluggish stock performance and stiff competition from a rising tech consortium.
<h2 class="wp-block-heading">The Disruptor: Palantir</h2>
Palantir, alongside Anduril Industries, is leading <a href="https://www.benzinga.com//node/42640010">a groundbreaking coalition</a> with Elon Musk&#8216;s SpaceX and OpenAI to revolutionize the $850 billion U.S. defense market. The goal? Outpace traditional contractors by integrating AI-powered solutions and autonomous systems. 
Palantir's AI Platform already works seamlessly with Anduril&#8217;s Lattice software, signaling a shift toward modern, agile defense technologies.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM.png" alt="" class="wp-image-703970" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064119/Screenshot-2024-12-23-at-5.04.06-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, PLTR stock is on a tear. Its share price of $80.55 is comfortably above the eight, 20 and 50-day simple moving averages (SMAs), signaling strong bullish momentum. However, with a relative strength index (RSI) of 70.81, it's entering overbought territory—a red flag for cautious investors.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/12/42620067/palantir-defies-gravity-army-deal-nasdaq-100-spotlight-fuel-rally">Palantir Defies Gravity: Army Deal, Nasdaq 100 Spotlight Fuel Rally</a>
<h2 class="wp-block-heading">The Titan: Lockheed Martin</h2>
Meanwhile, Lockheed is feeling the heat. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM.png" alt="" class="wp-image-703971" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23064219/Screenshot-2024-12-23-at-5.04.17-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The defense giant's stock, at $489.02, is below key moving averages, including its 200-day SMA of $510.22, indicating bearish sentiment. A relative strength index (RSI) of 29.59 suggests the stock is oversold, leaving a sliver of hope for a bounce-back.
Despite its legacy status and deep-rooted Pentagon ties, Lockheed faces mounting pressure to adapt as rivals like Palantir challenge its dominance with innovative, cost-efficient technologies.
<h2 class="wp-block-heading">The Verdict</h2>
Palantir's agility and tech-first approach make it a compelling contender in a sector ripe for disruption. Lockheed, however, isn't out of the fight—its oversold status might attract value-driven investors betting on a rebound.
As the defense industry evolves, this tech-versus-tradition showdown is one stock battle investors can't afford to ignore. 
The question remains: Can Lockheed innovate fast enough to fend off Palantir's charge, or is this the dawn of a new era?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42643303/us-stocks-to-open-higher-as-wall-street-expects-santa-rally-in-shortened-trading-week-microstrategy-palantir-qualcomm-among-stocks-in-focus">US Stocks To Open Higher As Wall Street Expects &#8216;Santa Rally&#8217; In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus</a></li>
</ul>
Image via Shutterstock

Long Ideas

Technicals

Tech

Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market

Piper Sandler analyst Crispin Love maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and raises the price target from $168 to $179.

Piper Sandler Maintains Neutral on Blackstone, Raises Price Target to $179

WIIM

NUVB

Nuvation Bio shares are trading higher after the company announced the FDA accepted the New Drug Application for taletrectinib for the treatment of advanced ROS1+ NSCLC.

Anebulo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise.
<ul>
<li>In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children</li>
<li>Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing</li>
<li>FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication</li>
<li>Anebulo plans to begin its Phase I SAD study of IV selonabant in healthy adults in 1H25</li>
<li>Anebulo entered into a definitive stock purchase agreement with 22NW, a company controlled by one of its directors, Nantahala Capital and an additional existing investor for the issuance and sale of 15.2 million shares of common stock for gross proceeds of $15 million in a private placement offering priced at-the-market under Nasdaq rules</li>
<li>In exchange for purchasing $10 million of shares of common stock in the private placement, Anebulo intends to modify the Loan and Security Agreement (LSA) that was entered into with 22NW and JFL Capital Management by reducing the maximum loan size to approximately $3 million, which reduces the LSA to just under the securitization threshold, and the removal of any securitization</li>
</ul>

Biotech

General

ANEB

Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.3%. Currently, Chubb has a market capitalization of $109.65 billion. 
Buying $1000 In CB: If an investor had bought $1000 of CB stock 20 years ago, it would be worth $7,098.87 today based on a price of $272.01 for CB at the time of writing.
<h3>Chubb's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734963313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

In the current session, Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) is trading at $111.71, after a 0.29% decrease. Over the past month, the stock fell by 4.62%, and in the past year, by 11.31%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1734963307_0.png" alt="Past Year Chart" />

<h3>Comparing Global Payments P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Global Payments has a lower P/E than the aggregate P/E of 46.95 of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734963307_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Global Payments

First Busey Corporation ("First Busey") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>), the holding company of Busey Bank, and CrossFirst Bankshares, Inc. ("CrossFirst") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFB#NASDAQ">CFB</a>), the holding company of CrossFirst Bank, today jointly announced that First Busey shareholders and CrossFirst shareholders have each voted to adopt and approve, as applicable, all proposals relating to the previously announced merger in which First Busey will acquire CrossFirst. The special shareholder meetings were held on Friday, December 20, 2024.

BUSE

First Busey And CrossFirst Bankshares Announce Each Co's Shareholder Approvals Of Merger

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and maintains $135 price target.

LGND

Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $135 Price Target

Loop Capital analyst Mark Schappel maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $185 to $205.

SNOW

Loop Capital Maintains Buy on Snowflake, Raises Price Target to $205

Nevada's Gaming Control Board also reported October Las Vegas Strip gaming win down 3.12% to $692.07M compared to last year. Publicly traded compan...

Nevada reports October statewide gaming win down 2.19% to $1.29B

Robinhood CEO Tenev 'keenly looking' into sports betting

There's a lot to be optimistic about in the Communication Services sector as 3 analysts just weighed in on VEON (VEON – Research Report), Take-Two ...

Analysts Offer Insights on Communication Services Companies: VEON (VEON), Take-Two (TTWO) and Genius Sports Limited (GENI)

Meeting to be held in New York on December 10 hosted by Benchmark. Published first on TheFly – the ultimate source for real-time, market-moving bre...

management to meet with Benchmark

Welcome to the latest edition of "Bet On It," where The Fly looks at news and activity in the sports betting and iGaming space. SECTOR NEWS: Senato...

Bet On It: Senator says FanDuel, DraftKings should face antitrust probe

An announcement from Genius Sports Limited ( ($GENI) ) is now available. Genius Sports Limited held its 2024 Annual General Meeting of Shareholders...

Genius Sports Limited Announces Results of 2024 Annual General Meeting

Welcome to the latest edition of "Bet On It," where The Fly looks at news and activity in the sports betting and iGaming space. SECTOR NEWS: Caesar...

Bet On It: Gambling.com to acquire Odds Holdings for $80M upfront

Nevada eyes requiring licenses for sports data trackers

The Gabelli International Small Cap Fund Q3 2024 Commentary

Welcome to the latest edition of "Bet On It," where The Fly looks at news and activity in the sports betting and iGaming space.&nbsp; SECTOR NEWS:&...

Bet On It: South Carolina advances legalized sports betting efforts

ACEL

BALY

BRAG

CDRO

CHDN

CNTY

DKNG

EVRI

FLUT

GAMB

GDEN

GENI

GLPI

HOOD

INSI

JNDOF

MCRI

MLCO

PENN

SGFEF

SGHC

SRAD

TTWO

VEON

WYNN

Press Releases

Genius Sports Launches GeniusIQ to Accelerate the AI Revolution in Global Sport

Genius Sports Announces Upcoming Conference Schedule

Genius Sports to Supply Semi-Automated Offside Technology for the Premier League

Genius Sports Limited Addresses Media Speculation Regarding a Potential Acquisition of Kambi Group plc

Genius Sports Announces Appointment of Mark Kropf as Group Chief Technology Officer

Genius Sports Launches FANHub, World's First Advertising & Activation Platform to Reach & Engage Sports Fans

Genius Sports to Announce Third Quarter 2024 Results on November 12

Los Angeles Rams launch Next Gen Stats-powered, in-stadium highlights through new collaboration with Genius Sports

First-Of-Its-Kind "EA Sports Madden NFL Cast" to Stream Live Exclusively on Peacock for Texans-Chiefs Matchup on Saturday Dec. 21 at 1 P.M. ET

TNT Sports, in Collaboration with NBA 2K and Genius Sports, to Present NBA 2K25 DataCast Alternative Telecast on truTV & Max for 2024 Emirates NBA Cup Knockout Round Coverage

Accel Entertainment

PlayAGS

Ballys

Boyd Gaming

Codere Online Luxembourg, S.A. - Ordinary Shares

Codere Online Luxembourg

Churchill Downs, Incorporated - Common Stock

Churchill Downs

Century Casinos

Caesars Entertainment, Inc. - Common Stock

Caesars Entertainment

DraftKings

Everi Hldgs

Full House Resorts

Golden Entertainment, Inc. - Common Stock

Golden Entertainment

International Game Technology Ordinary Shares

Intl Game Tech

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment

Light & Wonder

Las Vegas Sands

Monarch Casino & Resort, Inc. - Common Stock

Monarch Casino & Resort

MGM Resorts Intl

Melco Resorts & Entertainment Limited - American Depositary Shares

Melco Resorts and Enter

Studio City International Holdings Limited American depositary shares, each representing four Class A ordinary shares

Comments

Genius Sports

Actualités

Dernières nouvelles pour Genius Sports (NYSE:GENI) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL